OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

October 25th 2021

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

Dr. Wierda on Future Research Directions With MRD in CLL

October 25th 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Shah on the Potential Utility of NK Cells in Multiple Myeloma

October 25th 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

October 25th 2021

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer

October 25th 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Dr. Abutalib on Recent Updates in CLL

October 25th 2021

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

October 22nd 2021

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC

October 22nd 2021

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC

October 22nd 2021

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

Dr. Wierda on Ongoing Research Efforts Examining Fixed-Duration Strategies in CLL

October 21st 2021

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

October 21st 2021

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Shroff on the Importance of Targeted Therapy in Advanced Biliary Tract Cancer

October 21st 2021

Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.

Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

October 21st 2021

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Dr. Subudhi on the Integration of Antiandrogen Agents in mHSPC

October 21st 2021

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

Dr. McKinney on the Expanding Role of BTK Inhibitors in MCL

October 21st 2021

Matthew S. McKinney, MD, discusses the expanding role of BTK inhibitors in mantle cell lymphoma.

Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma

October 21st 2021

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Dr. Danilov on the Safety Profile of Entospletinib Plus Obinutuzumab in CLL

October 21st 2021

Alexey V. Danilov, MD, PhD, discusses the safety profile of entospletinib plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Zhen on the Need for Novel Therapies in Poorly Differentiated Small-Cell-Type NETs

October 21st 2021

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma

October 20th 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma.

Dr. Thompson on the Safety Profile of Pirtobrutinib in Patients With Richter Transformation

October 20th 2021

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.